These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22008920)

  • 1. Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity.
    Huang GZ; Tang YH; Wang BY; Zhang B; Hu TJ; Zhang L; Zhang XY; Zhong Y
    Saudi Med J; 2011 Oct; 32(10):1017-21. PubMed ID: 22008920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.
    Shimabukuro M; Tanaka H; Shimabukuro T
    J Hypertens; 2007 Apr; 25(4):841-8. PubMed ID: 17351377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients.
    Chujo D; Yagi K; Asano A; Muramoto H; Sakai S; Ohnishi A; Shintaku-Kubota M; Mabuchi H; Yamagishi M; Kobayashi J
    Hypertens Res; 2007 Dec; 30(12):1205-10. PubMed ID: 18344626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
    Bahadir O; Uzunlulu M; Oguz A; Bahadir MA
    Hypertens Res; 2007 Jan; 30(1):49-53. PubMed ID: 17460371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
    Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K
    Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO).
    Murakami K; Wada J; Ogawa D; Horiguchi CS; Miyoshi T; Sasaki M; Uchida HA; Nakamura Y; Makino H
    Diab Vasc Dis Res; 2013 Jan; 10(1):93-6. PubMed ID: 22561230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.
    Usui I; Fujisaka S; Yamazaki K; Takano A; Murakami S; Yamazaki Y; Urakaze M; Hachiya H; Takata M; Senda S; Iwata M; Satoh A; Sasaoka T; Ak ND; Temaru R; Kobayashi M
    Diabetes Res Clin Pract; 2007 Aug; 77(2):210-4. PubMed ID: 17240472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial.
    Chetty VT; Damjanovic S; Gerstein H; Singh N; Yusuf S; Anand SS; Sharma AM
    Blood Press; 2014 Feb; 23(1):54-60. PubMed ID: 23731019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes.
    Kobayashi K; Ohno Y; Takenaka T; Ikeda N; Okada H; Kanno Y; Suzuki H
    Clin Exp Hypertens; 2011; 33(2):100-5. PubMed ID: 21269058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
    Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
    Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
    Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
    Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
    Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
    Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan and metabolic syndrome after heart transplantation.
    Luknar M; Goncalvesova E; Lesny P; Fabian J
    Clin Transplant; 2010; 24(1):36-9. PubMed ID: 19222503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
    Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
    Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats.
    Younis F; Oron Y; Limor R; Stern N; Rosenthal T
    Metabolism; 2012 Feb; 61(2):164-74. PubMed ID: 21820685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan improves cardiometabolic profile in obese patients with arterial hypertension.
    Kubik M; Chudek J; Adamczak M; Wiecek A
    Kidney Blood Press Res; 2012; 35(4):281-9. PubMed ID: 22378488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
    Souza-Mello V; Gregório BM; Cardoso-de-Lemos FS; de Carvalho L; Aguila MB; Mandarim-de-Lacerda CA
    Clin Sci (Lond); 2010 Jun; 119(6):239-50. PubMed ID: 20415664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
    Mori H; Okada Y; Arao T; Nishida K; Tanaka Y
    Adv Ther; 2012 Jul; 29(7):635-44. PubMed ID: 22821644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients.
    de Luis DA; Conde R; González-Sagrado M; Aller R; Izaola O; Dueñas A; Pérez Castrillón JL; Romero E
    Nutr Hosp; 2010; 25(2):275-9. PubMed ID: 20449538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment.
    Fuke Y; Fujita T; Satomura A; Wada Y; Matsumoto K
    Diabetes Technol Ther; 2010 May; 12(5):393-8. PubMed ID: 20388049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.